We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Urinary Epidermal Growth Factor Investigated for Diabetes Nephropathy

By LabMedica International staff writers
Posted on 06 Aug 2021
Type 1 diabetes mellitus is an auto-immune metabolic disease with chronic hyperglycemia. More...
For many patients with type 1 diabetes (T1DM), it is challenging to maintain near-normal glucose blood levels and to reduce the risk of both acute (hypoglycemia, ketoacidosis) and chronic microvascular (retinopathy, neuropathy and nephropathy) and macrovascular complications.

Epidermal growth factor (EGF) stimulates cell growth, proliferation and differentiation by binding to its receptor EGFR. In the kidney, EGF is involved in the repairing process of kidney structures. EGF is synthetized along the kidney tubules and excreted into the urine, making urinary EGF a potential hallmark for regenerative functional capacity of the tubulointerstitial compartment of the kidney.

Pediatric Nephrologists at the University of Antwerp (Antwerp, Belgium) and their colleagues included in a study 158 children with type 1 diabetes mellitus and 40 healthy controls. Serum and urine samples were collected three times with an interval of at least one month to determine creatinine (serum and urine), epidermal growth factor and albumin (urine).

The team explored whether urinary epidermal growth factor (uEGF) might serve as an early marker of diabetes nephropathy compared to microalbuminuria in children and adolescents. Urinary EGF was measured using an EGF human Elisa kit (Invitrogen, Waltham, MA, USA). The detection limit of this assay was 3.9 pg/mL. For the comparative analysis in children and adolescents, the scientists corrected the values accounting for growth. Serum and urine creatinine, urine total protein and microalbuminuria were analyzed with the Dimension Vista system (Siemens Healthcare Diagnostics, Deerfield, MA, USA).

The investigators reported that urinary EGF was significantly lower in T1DM compared to healthy children. In children with T1DM, the mean duration of diabetes was 5.49 ± 3.29 years with a mean HbA1c of 7.7 ± 1.0% (60 ± 11 mmol/mol) and a mean insulin need of 0.87 ± 0.20 units/kg/day. Forty-four children (27.8%) were younger than six years when T1DM was diagnosed. A relatively lower glomerular filtration rate (eGFR) was associated with a decreased uEGF. The uEGF was independently associated with eGFR in a multivariate analysis. None of the patients with an eGFR < 90 mL/min/1.73 m2 had microalbuminuria > 30 mg/g creatinine, while 9.5% and 10.1% of the patients with an eGFR 90–110 mL/min/1.73 m2 and > 110 mL/min/1.73 m2 respectively did have microalbuminuria > 30 mg/g creatinine.

The authors concluded that uEGF is a promising ‘next generation’ biomarker associated with early signs of diabetes nephropathy in children and adolescents and worth further investigation as a single biomarker or as one of a multi-biomarker panel. The study was published on July 7, 2021 in the journal Diabetes Research and Clinical Practice.

Related Links:

University of Antwerp
Invitrogen
Siemens Healthcare Diagnostics 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.